Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aripiprazole + valproate
- Development stage
- Preclinical
- Lead developer
- Taiho Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Aripiprazole + valproate is a fixed-dose combination (FDC) tablet formulation comprising the atypical antipsychotic aripiprazole and the mood stabilizer divalproex sodium (valproate). Aripiprazole acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors, providing stabilizing effects on neurotransmission. Valproate's mechanism involves increasing gamma-aminobutyric acid (GABA) levels in the brain and modulating voltage-gated sodium channels to stabilize neuronal activity. This combination is primarily indicated for the treatment of manic or mixed episodes associated with bipolar I disorder. The development of the FDC aims to improve patient compliance and simplify dosing regimens compared to the co-administration of individual tablets.
- Other names
- aripiprazole + divalproex sodiumaripiprazole/valproate fixed-dose combination
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))NaV (Voltage-gated sodium channels)HDAC (HDAC family)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)CaV (Voltage-gated calcium channel protein complex)
Beyond the preview
Go deeper on aripiprazole + valproate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aripiprazole + valproate.